Signal Inc. (TSXV:SEGN) (“Cignal” or the “Company”), a global leader in clinical decision support solutions that enforce patient-centered medication safety standards, today announced that its Israeli operating subsidiary, Cignal eHealth Ltd., has been awarded the prestigious award. gold mark A high institutional quality honor given by the Standards Institute of Israel, to organizations that have embedded a culture of excellence in their management systems, processes and product lifecycle. The Gold Mark certification further strengthens Signal’s commercialization-readiness and its position as an enterprise-grade platform trusted by leading healthcare systems.
A historic mark in quality leadership
The Gold Mark is specifically awarded to organizations that have adopted quality and excellence as a fundamental organizational ethos, not just a compliance practice, and which simultaneously hold three or more quality certification marks attesting to the alignment of their management systems, processes and products with Israeli and international standards. It represents institutional rigor, operational discipline and an unwavering commitment to safety and performance.
Cignal eHealth Ltd. received the Gold Mark in recognition of holding all three of the following certification marks issued by the Israel Standards Institute:
- ISO 13485:2016: Medical Device Quality Management System, certifying that Cignal’s quality management processes meet the most demanding international standards applicable to medical device manufacturers and suppliers;
- ISO 27799: Information Security Management in Health, confirming that Signal’s data governance and information security architecture is consistent with sector-specific requirements for managing sensitive health data; And
- ISO 27001:2022: Information Security Management System (ISMS), a certified and independently audited information security management framework across the entire organization.
Gold Mark Certificate Signed for 2026 Dr. Gilad GolubCEO of the Standards Institute of Israel, and avital weinbergVice President of Quality and Certification Division.
About Signal Inc.
Signal Inc. (TSXV: SEGN) is a global leader in clinical decision support, applying patient-centered medication safety standards to improve outcomes in health care systems. Cignal’s proprietary platform is deployed across major hospital networks and provides real-time, point-of-care medication safety intelligence. For more information visit www.segnal.com.
contact information
Elad Bibi-Aviv
chief executive officer
+1 (929) 248 4652
arx investor relations
North American Equity Desk
Seegnal@arxhq.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
